Central India Chronicle

Propulsion of Medullary Thyroid Cancer Clinical Trial Pipeline as Novel and Extensive 15+ Therapies Likely to Enter in the Domain | DelveInsight

 Breaking News
  • No posts were found

Propulsion of Medullary Thyroid Cancer Clinical Trial Pipeline as Novel and Extensive 15+ Therapies Likely to Enter in the Domain | DelveInsight

August 26
04:50 2023
Propulsion of Medullary Thyroid Cancer Clinical Trial Pipeline as Novel and Extensive 15+ Therapies Likely to Enter in the Domain | DelveInsight

(Albany, United States) As per DelveInsight’s assessment, globally, the Medullary Thyroid Cancer Pipeline constitutes 15+ key companies continuously working towards developing 15+ Medullary Thyroid Cancer Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Medullary Thyroid Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Medullary Thyroid Cancer NDA approvals (if any), and product development activities comprising the technology, Medullary Thyroid Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Medullary Thyroid Cancer Pipeline treatment landscape of the report, click here @ Medullary Thyroid Cancer Pipeline Outlook

 

Key Takeaways from the Medullary Thyroid Cancer Pipeline Report

  • DelveInsight’s Medullary Thyroid Cancer Pipeline analysis depicts a robust space with 15+ active players working to develop 15+ pipeline treatment therapies.
  • The leading companies working in the Medullary Thyroid Cancer Market include Bristol-Myers Squibb, Takeda, NantCell Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Bayer, Novartis, Hutchison Medipharma Limited, Turning Point Therapeutics, Inc., and others.
  • Promising Medullary Thyroid Cancer Pipeline Therapies in the various stages of development include Selpercatinib, Cabozantinib, Vandetanib, Pralsetinib, LOXO-292, Anlotinib Hydrochloride Capsule, HA121-28 tablets, and others.
  • On July 2023, Loxo Oncology Inc. announced a study of phase 3 clinical trials for Selpercatinib, Cabozantinib, and Vandetanib. The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
  • On July 2023, Exelixis announced a study of phase 4 clinical trials for Cabozantinib (XL184) 140 mg. The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC. It will test if the lower dose results in similar progression free survival (PFS) and overall response rate (ORR) with fewer adverse events compared to the PFS, ORR and adverse events found in previous clinical trials of 140 mg.

 

Medullary Thyroid Cancer Overview

Medullary thyroid cancer, or MTC, is a cancer that forms in the thyroid. The thyroid is a gland located in the front of your neck, just below the Adam’s apple. It is responsible for sending out hormones to the rest of your body.

 

For further information, refer to the detailed Medullary Thyroid Cancer Unmet Needs, click here for Medullary Thyroid Cancer Ongoing Clinical Trial Analysis

 

Medullary Thyroid Cancer Emerging Drugs Profile

  • Nivolumab: Bristol-Myers Squibb
  • Regorafenib: Bayer

 

Medullary Thyroid Cancer Pipeline Therapeutics Assessment

There are approx. 15+ key companies which are developing the therapies for Medullary Thyroid Cancer. The companies which have their Medullary Thyroid Cancer drug candidates in the most advanced stage, i.e. phase II include, Bayer.

 

Request a sample and discover the recent advances in Medullary Thyroid Cancer Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Medullary Thyroid Cancer Segmentation

 

Medullary Thyroid Cancer Drugs and Companies

  • Selpercatinib: Loxo Oncology Inc.
  • Cabozantinib: Eli Lilly and Company
  • Pralsetinib: Hoffmann-La Roche

 

Medullary Thyroid Cancer Therapeutics Assessment

  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

 

Some of the Companies in the Medullary Thyroid Cancer Therapeutics Market include-

Bristol-Myers Squibb, Takeda, NantCell Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Bayer, Novartis, Hutchison Medipharma Limited, Turning Point Therapeutics, Inc., and others.

 

Dive deep into rich insights for drugs for Medullary Thyroid Cancer Pipeline, click here @ Medullary Thyroid Cancer Unmet Needs and Analyst Views

 

Scope of the Medullary Thyroid Cancer Pipeline Report

  • Coverage- Global
  • Companies- Bristol-Myers Squibb, Takeda, NantCell Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Bayer, Novartis, Hutchison Medipharma Limited, Turning Point Therapeutics, Inc., and others.
  • Therapies- Selpercatinib, Cabozantinib, Vandetanib, Pralsetinib, LOXO-292, Anlotinib Hydrochloride Capsule, HA121-28 tablets, and others.
  • Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Medullary Thyroid Cancer Merger and acquisitions, Licensing Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Medullary Thyroid Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Medullary Thyroid Cancer – DelveInsight’s Analytical Perspective
  7. Mid Stage Products (Phase II)
  8. Nivolumab: Bristol-Myers Squibb
  9. Drug profiles in the detailed report…..
  10. Early Stage Products (Phase I)
  11. Drug Name: Company Name
  12. Drug profiles in the detailed report…..
  13. Inactive Products
  14. Medullary Thyroid Cancer Key Companies
  15. Medullary Thyroid Cancer Key Products
  16. Medullary Thyroid Cancer- Unmet Needs
  17. Medullary Thyroid Cancer- Market Drivers and Barriers
  18. Medullary Thyroid Cancer- Future Perspectives and Conclusion
  19. Medullary Thyroid Cancer Analyst Views
  20. Medullary Thyroid Cancer Key Companies
  21. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services